{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-000247","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.811470+00:00","generated_at":"2026-05-27T08:36:38.938794+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion reports preclinical data: SIL-204 systemic admin reduces pancreatic tumor growth ~50%","bullets":["Extended-release SIL-204 reduced tumor growth ~50% after 30 days; ~50% of tumors showed complete necrosis in G12D xenografts.","Subcutaneous SIL-204 inhibited tumor growth in mouse metastatic pancreatic orthotopic models.","Single systemic dose maintained drug levels in rat plasma and tissues for over 56 days.","SIL-204 inhibits multiple KRAS mutations: G12D, G12V, G12R, Q61H, and G13D."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-000247","json":"https://secwatch.observer/filing/0001178913-25-000247.json","markdown":"https://secwatch.observer/filing/0001178913-25-000247.md","text":"https://secwatch.observer/filing/0001178913-25-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/0001178913-25-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/zk2532610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:36:38.938794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}